UCSD Molecular Tumor Board Aids Patient Care Decisions in Age of NGS Tests | GenomeWeb

NEW YORK (GenomeWeb) – Academic medical centers that have begun incorporating next-generation sequencing-based tests for cancer patients often rely on molecular tumor boards to help interpret the results in the context of other clinical features, such as the patient's medical history and pathology results. Tumor boards are not new in cancer care and are a common tool used to discuss complicated cases, patients with rare cancer, or patients without an obvious course of treatment.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.